This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Citizens Financial Services (CZFS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
CZFSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
by Zacks Equity Research
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
RDYPositive Net Change RHHBYPositive Net Change AMGNPositive Net Change ALVOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Is BMY's Deep Pipeline the Key to Its Next Growth Phase?
by Ekta Bagri
BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026?
by Zacks Equity Research
ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid margin expansion.
GRFSPositive Net Change ADMAPositive Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche's Genentech Expands Investment in North Carolina Facility to $2B
by Zacks Equity Research
Roche more than doubles Genentech's Holly Springs biomanufacturing investment to approximately $2B, boosting U.S. supply-chain resilience and metabolic drug production.
NVSPositive Net Change RHHBYPositive Net Change JNJPositive Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission
by Zacks Equity Research
IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.
ALKSPositive Net Change FOLDNegative Net Change KRYSPositive Net Change IBRXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
by Zacks Equity Research
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
NVOPositive Net Change ALKSPositive Net Change FOLDNegative Net Change KRYSPositive Net Change
biotechnology biotechs cell-therapy medical pharmaceuticals
BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
Bristol Myers Squibb and GSK stack up differently on growth, debt, pipelines and returns, making the stock-picking decision far from obvious
GSKPositive Net Change BMYPositive Net Change PFEPositive Net Change BNTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy?
by Ahan Chakraborty
CRMD and MIRM are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
PFEPositive Net Change CRMDPositive Net Change MIRMNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Shares Jump as Supreme Court Agrees to Review Key Roundup Case
by Zacks Equity Research
BAYRY jumps 6.4% after the Supreme Court agrees to review the Durnell Roundup case, a key test of federal preemption in glyphosate litigation.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results
by Zacks Equity Research
IBRX shares surge after updated data from the study of CD19 t-haNK show durable complete responses in Waldenstrom lymphoma without chemo or lymphodepletion.
RHHBYPositive Net Change ALKSPositive Net Change KRYSPositive Net Change IBRXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already?
by Ahan Chakraborty
NVO shares jump 9.1% as early U.S. prescriptions for oral Wegovy show strong first-week demand after its early January launch.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
by Ekta Bagri
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
SRPTPositive Net Change SLDBPositive Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Erasca Stock Surges 42% in a Week: Here's What You Should Know
by Zacks Equity Research
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
ALKSPositive Net Change FOLDNegative Net Change KRYSPositive Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Implied Volatility Surging for Vertex Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to VRTX stock based on the movements in the options market lately.
VRTXPositive Net Change
biotechnology biotechs medical
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
PCRXPositive Net Change
biotechnology biotechs medical
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
by Zacks Equity Research
APLS stock plunges 23% in a week after reporting $190 million in preliminary Q4 U.S. net product revenues, as weaker Syfovre sales and mixed Empaveli uptake disappoint investors.
ALKSPositive Net Change FOLDNegative Net Change KRYSPositive Net Change APLSPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?
by Ahan Chakraborty
Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
After Golden Cross, Adeia (ADEA)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ADEAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bayer Stock Jumps on Nubeqa Outlook, Presents Pharma Strategy
by Zacks Equity Research
BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term. Bayer also announced pharma priorities at J.P. Morgan Healthcare Conference.
JNJPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026?
by Ekta Bagri
KROS shares are up 85.6% in a year, driven by a strategic review and pipeline progress led by KER-065 and elritercept, which have fueled investor enthusiasm.
SRPTPositive Net Change TAKNegative Net Change KROSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Positive Data on Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline setbacks and rising competition.
BMYPositive Net Change JNJPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
by Zacks Equity Research
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
ALKSPositive Net Change FOLDNegative Net Change PCRXPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals
BNP Paribas SA (BNPQY) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
BNPQYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook
by Zacks Equity Research
ADMA expects 2025 revenues of approximately $510-$511 million, raising 2026 guidance on strong Asceniv demand and margin expansion.
FOLDNegative Net Change ADMAPositive Net Change KRYSPositive Net Change
biotechnology biotechs medical pharmaceuticals